Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq set for sharp drop as Amazon, Intel amplify AI spending worries
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts AMRX Hot Sheet
Price: $21.35 --0%
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 43 | New: 7
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 43 | New: 7
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Amneal Pharmaceuticals (NASDAQ: AMRX) to $11.00 (from $10.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Precision Drilling (PD:CN) (PDS) PT Raised to Cdn$170 at RBC Capital
- Builders FirstSource (BLDR) PT Lowered to $75 at UBS
- Textron (TXT) PT Raised to $94 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
